Search

Innate Pharma SA

Fermé

1.854 3

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.8439999999999999

Max

1.8559999999999999

Chiffres clés

By Trading Economics

Revenu

3.4M

-21M

Ventes

531K

4.9M

Marge bénéficiaire

-439.177

Employés

174

EBITDA

-2M

-25M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+20.41% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

13M

170M

Ouverture précédente

-1.15

Clôture précédente

1.854

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Innate Pharma SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 oct. 2025, 18:41 UTC

Résultats

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 oct. 2025, 18:31 UTC

Résultats

Correction to Procter & Gamble to Focus on Innovation

24 oct. 2025, 16:25 UTC

Principaux Mouvements du Marché

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Résultats

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Résultats

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Résultats

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Résultats

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Résultats

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Résultats

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 oct. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 oct. 2025, 18:52 UTC

Résultats

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:41 UTC

Résultats

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 oct. 2025, 18:03 UTC

Résultats

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 oct. 2025, 18:02 UTC

Résultats

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 oct. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 oct. 2025, 16:57 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 oct. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 oct. 2025, 16:44 UTC

Market Talk
Résultats

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 oct. 2025, 16:39 UTC

Market Talk
Résultats

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 oct. 2025, 16:33 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:23 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 16:07 UTC

Résultats

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Innate Pharma SA prévision

Objectif de Prix

By TipRanks

20.41% hausse

Prévisions sur 12 Mois

Moyen 2.228 EUR  20.41%

Haut 2.23 EUR

Bas 2.23 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.91 / 2.1Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
help-icon Live chat